A Post-Marketing Active Surveillance Study to Evaluate the Risk of Guillain-Barré Syndrome, Acute Disseminated Encephalomyelitis, and Atrial Fibrillation in Adults 50 Years and Older Vaccinated with GSK’s Arexvy Vaccine in the United States
March 6, 2025
Authors:
Harvard Pilgrim Health Care Institute, CVS Health, Carelon Research, Humana HealthCare, HealthPartners Institute, GlaxoSmithKline
A Post-Marketing Active Surveillance Study to Evaluate the Risk of Guillain-Barré Syndrome, Acute Disseminated Encephalomyelitis, and Atrial Fibrillation in Adults 50 Years and Older Vaccinated with GSK’s Arexvy Vaccine in the United States
